Summary: Vivos Therapeutics Inc has announced that the American Medical Association (AMA) will introduce new Current Procedural Terminology (CPT) codes for Vivos CARE oral appliances, effective Jan 1, 2025. These codes are expected to facilitate insurance coverage and reimbursement for the treatment of obstructive sleep apnea (OSA) in both adults and children. Vivos’ airway remodeling devices are the only FDA-cleared oral appliances for moderate to severe OSA. This development coincides with recent regulatory approvals and is aimed at making OSA treatment more accessible and affordable.
Key Takeaways:
- New AMA CPT Codes: The new medical codes, effective January 2025, will facilitate insurance billing by commercial payers for Vivos CARE oral appliances.
- FDA-Cleared Devices for Moderate to Severe OSA: Vivos CARE oral appliances are the only FDA-cleared devices for treating moderate to severe obstructive sleep apnea.
- Increased Accessibility and Affordability: Vivos expects that these new codes, along with its regulatory approvals and marketing efforts, will increase access to affordable OSA treatment for a broader demographic.
Vivos Therapeutics Inc, a medical technology company specializing in the development of treatments for sleep-related breathing disorders, including obstructive sleep apnea (OSA) in adults and children, announced the American Medical Association (AMA) has issued new Current Procedural Terminology (CPT) medical codes applicable to all Vivos CARE oral appliances, which will become effective Jan 1, 2025.
Vivos Chairman and CEO, Kirk Huntsman, says in a release, “This is exciting news for OSA patients and medical providers who treat sleep breathing disorders. Our CARE oral medical devices are the only ones cleared by the US Food and Drug Administration for the treatment of moderate to severe OSA, and these new medical codes will now facilitate coverage and reimbursement by commercial medical insurance payers.
[RELATED: Vivos’ Oral Appliances Receive Full Approval for Medicare Reimbursement]
“From Vivos’ perspective, we believe this will enable a larger number of patients from most demographics to access our breakthrough, proprietary airway remodeling technology and more effectively treat their OSA. This development comes at an opportune moment for Vivos as our recent regulatory approvals, coupled with our new alliance-based marketing and distribution model and now these new codes put Vivos in an improved position to drive revenue growth.”
AMA Introduces 420 Updates in CPT 2025, Including New Codes for Vivos
In a recent press release, the AMA explained, “The emergence of medical innovations, new technologies, and cutting-edge procedures spurred most of the annual changes presented in the release of the Current Procedural Terminology (CPT) 2025, the nation’s uniform data-sharing code set for medical procedures and services. There are 420 overall updates in the CPT 2025 code set, including 270 new codes, 112 deletions, and 38 revisions.”
AMA President Bruce A. Scott, MD, says in a release, “The CPT code set is the foundation for the efficient and effective exchange of standardized information in a data-driven health system…with the goal of delivering better patient care, improved outcomes, and lower costs.”
Huntsman concludes in a release, “With these new CPT codes, we are taking a major step towards making OSA treatment more accessible and affordable for patients nationwide, including children ages 6 to 17. This approval highlights our commitment to ensuring more people can receive the care they need while receiving greater support from their healthcare insurance plans.”
Photo caption: VIvos’ mRna oral appliance
Photo credit: Vivos Therapeutics/file photo
